CYP46A1 and Parkinson disease: For instance, chronic EFV treatment in 5xFAD mice increased GFAP levels (86), whereas in the M83 transgenic mouse model of PD injected with preformed fibrils, EFV treatment elevated CYP46A1 levels while reducing reactive astrocytes and microglia (87).